Answers are grounded in this paper and cite their sources.
BACKGROUNDLiver fibrosis is a critical stage in chronic liver disease progression, and early identification of high-risk individuals is essential.However, FibroTouch, although noninvasive, is expensive and not widely accessible for large-scale screening.AIM To develop and validate a machine learning model using routine clinical indicators to predict ≥ F2 fibrosis in health examination populations.METHODS This retrospective multicenter cross-sectional diagnostic-prediction study included a single-center cohort of 13899 participants from the First Affiliated Hospital of Zhejiang University School of Medicine (June 2021 to August 2025).The development cohort was randomly split 8:2 into training (n = 11119) and internal validation (n = 2780) sets.The tuned original model was recalibrated using a later same-hospital cohort (n = 2363; September 2025 to July 2026).Both original and recalibrated models underwent independent geographic external validation at Sichuan Provincial People's Hospital (n = 309). RESULTSSix clinical variables (body mass index, fasting insulin, alanine aminotransferase, waist circumference, triglycerides, and cholinesterase) were selected.The random forest (RF) model achieved an area under the curve (AUC) of 0.846 [95% confidence interval (CI): 0.806-0.885]and Brier score of 0.032 (95%CI: 0.028-0.037),significantly outperforming all traditional scores.Calibration was satisfactory, and decision curve analysis confirmed net clinical benefit.In the temporal cohort, the original model showed an AUC of 0.766 4 / 42 (95%CI: 0.713-0.815)and was subsequently recalibrated.In the independent geographic external validation cohort from Sichuan Province, the original and recalibrated models achieved AUCs of 0.718 (95%CI: 0.565-0.844)and 0.718 (95%CI: 0.565-0.844),respectively.Subgroup analyses showed consistent performance across age, sex, and comorbidities. CONCLUSIONThis six-indicator RF model offers an inexpensive, effective screening tool for significant liver fibrosis in Chinese individuals; however, the results should be interpreted cautiously as the reference was FibroTouch, not biopsy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: